DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations

European Journal of Hospital Pharmacy: Science and Practice- Belgium

doi 10.1136/ejhpharm-2013-000276.309

Full Text

Abstract

Available in

Categories

Date

March 1, 2013

Authors

V Escudero-Vilaplana

JM López-Gómez

A Vega-Martínez

A Ais-Larisgoitia

B Marzal-Alfaro

A Ribed-Sánchez

P Arrabal-Durán

A Giménez-Manzorro

M Sanjurjo-Sáez

Publisher

BMJ

Related search

PCN34 Cost Analysis of Anemia Treatment With Erythropoiesis-Stimulating Agents (ESAs) in Cancer Patients Receiving Chemotherapy in Italy

Value in Health

Occupational Health

English

Factors Stimulating Erythropoiesis in Frogs

English

Differential Modulation of Angiogenesis by Erythropoiesis-Stimulating Agents in a Mouse Model of Ischaemic Retinopathy

Multidisciplinary

English

Intravenous Iron and Erythropoiesis-Stimulating Agents in Haemodialysis: A Systematic Review and Meta-Analysis

English

Erythropoiesis-Stimulating Agents Increase the Risk of Acute Stroke in Patients With Chronic Kidney Disease

Kidney International

English

Assessing the Quality of Prescribing and Monitoring Erythropoiesis-Stimulating Agents in the Nursing Home Setting

Journal of the American Medical Directors Association

English

Association Between High-Dose Erythropoiesis-Stimulating Agents, Inflammatory Biomarkers, and Soluble Erythropoietin Receptors

English

Treatment Options for Anemia, Taking Risks Into Consideration: Erythropoiesis-Stimulating Agents Versus Transfusions

Cancer Research

English

Effect of Long-Acting Erythropoiesis-Stimulating Agents on Hemoglobin Levels at the Initiation of Dialysis

Renal Replacement Therapy

English